
Fasiha Kanwal
Michael E. DeBakey VAMC
Fasiha Kanwal, MD, MSHS is the Nancy Chang Endowed Professor of Medicine, Director of the Institute for Clinical and Translational Research, and associate dean for clinical and translational research at Baylor College of Medicine. She also serves as the contact principal investigator for Baylor College of Medicine and University of Houston new CTSA grant. Dr. Kanwal has been recognized with numerous awards for her research on risk and risk factors for hepatocellular cancer and quality of care delivered to patients with liver disease. With over 350 published manuscripts to her credit and a robust track record of federal funding, she is among the top 2% of most frequently cited scientists. She served as the Chief for the Section of Gastroenterology and Hepatology at Baylor College of Medicine (2007-2025) and as the first women editor-in-chief of a major clinical journal in gastroenterology and hepatology (2007-2022). She is an elected member of the American Society for Clinical Investigators (ASCI) and the American Association of Physicians (AAP).
Appearances
- DateMay 6, 2023SOCIETY: AASLD
Presenter
Michael E. DeBakey VAMC - DateMay 9, 2023SOCIETY: AASLD
Presenter
Michael E. DeBakey VAMC - DateMay 8, 2023BACKGROUND AND AIMS: Screening tools are needed for early detection of NAFLD-fibrosis. We aimed to identify risk factors for NAFLD-fibrosis in the multiethnic population of the U.S. and thus accelerate development of equitable screening tools…
Presenter
Michael E. DeBakey VAMCSpeakers
Baylor College of Medicine - DateMay 20, 2024
Presenters
Mayo ClinicMichael E. DeBakey VAMC - DateMay 21, 2024BACKGROUND: With the recent increase in metabolic liver diseases and viral hepatitis on anti-viral agents, risk stratification biomarkers are urgently needed to identify cirrhosis patients who should be prioritized for hepatocellular carcinoma (HCC) screening for early detection…
Presenter
Speakers
University of MichiganMayo Foundation for Medical Education and ResearchBaylor College of MedicineBaylor University Medical CenterMichael E. DeBakey VAMCBaylor College of MedicineUT Southwestern Medical CenterUniversity of Texas Southwestern Medical Center - DateMay 21, 2024BACKGROUND. Several inflammatory and metabolic biomarkers have been associated with hepatocellular carcinoma (HCC) risk in phase I and II biomarker studies but not in longitudinal studies…
Presenter
Baylor College of MedicineSpeakers
Michael E. DeBakey VAMCBaylor College of MedicineUT Southwestern Medical CenterBaylor University Medical Center - DateMay 21, 2024
Presenter
Michael E. DeBakey VAMC - DateMay 18, 2024BACKGROUND: Patients with MASLD and diabetes have an increased risk of cirrhosis and hepatocellular cancer (HCC). Recent studies show that glucagon-like peptide-1 (GLP-1) agonists, such as semaglutide, are effective in improving liver inflammation in MASLD…
Presenter
Michael E. DeBakey VAMCSpeakers
The Perelman School of Medicine at the University of PennsylvaniaBaylor College of Medicine - DateMay 21, 2024BACKGROUND: Current understanding of the rates and trajectories of progression to cirrhosis complications is derived from outdated data. We examined the progression patterns of cirrhosis and their implications, focusing on the different outcomes of prolonged illness _vs_…
Speakers
Baylor College of MedicinePresenter
Michael E. DeBakey VAMC - DateMay 18, 2024ASSOCIATION OF GLUCAGON-LIKE PEPTIDE-1 AGONISTS WITH CIRRHOSIS AND HEPATOCELLULAR CANCER IN METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Moderators
Stanford UniversityDuke UniversitySpeakers
Michael E. DeBakey VAMCUniversity of Miami